Status:
UNKNOWN
ADD-ON Study to Existing Hypoparathyroidism Studies
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Hypoparathyroidism
Eligibility:
All Genders
18-85 years
Phase:
PHASE3
Brief Summary
The purpose of this protocol is to add on additional exploratory studies to investigate changes in bone quality parameters with PTH(1-84) treatment of hypoparathyroidism. In addition to the biochemica...
Detailed Description
In this protocol, we will investigate the mechanisms by which PTH(1-84) treatment improves bone quality in patients with hypoparathyroidism. Detailed imaging, cellular and biochemical studies will be ...
Eligibility Criteria
Inclusion
- active participation in the CL1-11-040, PAR-C10-007 or PAR-C10-008 Studies sponsored by NPS Pharmaceuticals.
- active participation in the HEXT Study of Dr. John Bilezikian.
Exclusion
- \- not being a participant of the CL1-11-040, PAR-C10-007 or PAR-C10-008 Studies sponsored by NPS Pharmaceuticals or the HEXT Study of Dr. John Bilezikian.
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2021
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT00856401
Start Date
September 1 2010
End Date
June 30 2021
Last Update
February 28 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University Medical Center
New York, New York, United States, 10032